Author + information
- Mistre Alemayehu,
- Richard Kim,
- Sabrina Wall,
- Sabrina D'Alfonso,
- Sara LeMay,
- Ronit Lavi,
- Inna Gong and
- Shahar Lavi
Background: Ticagrelor has been shown to reduce the incidence of cardiovascular events compared to clopidogrel. Ticagrelor leads to increased adenosine levels, a known modulator of vascular tone. Ticagrelor's protective effects may therefore be mediated by adenosine.
Methods: Microsvascular endothelial function was assessed using the EndoPAT system by measuring reactive hyperemia index (RHI). Participants with a history of coronary artery disease and endothelial dysfunction (RHI less than 2) were enrolled. All patients were treated with ticagrelor and clopidogrel in a cross-over manner. Each drug was administered for 21 days in a random order. Endothelial function was assessed at baseline and after treatment with each agent at peak drug levels (30 minutes post-clopidogrel and 2 hours post-ticagrelor dose). Treatments were compared using two-tailed t-tests.
Results: Forty-five patients (91% male) aged 64±8 years were included. Cardiovascular comorbidities included history of myocardial infarction (64%), prior revascularization (96%), dyslipidemia (76%), hypertension (64%), diabetes (27%) and history of smoking (82%). RHI improved with both therapies and was more pronounced with ticagrelor (Figure).
Conclusions: Short term therapy with ticagrelor or clopidogrel improves microvascular endothelial function. The effect of ticagrelor is more robust compared to clopidogrel and may contribute to the overall beneficial clinical effect of ticagrelor.
Moderated Poster Contributions
Vascular Medicine Moderated Poster Theater, Poster Hall, Hall C
Saturday, March 18, 2017, 12:30 p.m.-12:40 p.m.
Session Title: Uncovering the Intricacies of Vascular Function
Abstract Category: 40. Vascular Medicine: Non Coronary Arterial Disease
Presentation Number: 1228M-03
- 2017 American College of Cardiology Foundation